Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-exposure prophylaxis with favipiravir among household close contacts to confirmed COVID-19 cases
TCTR20210909002Phase 3Not yet recruiting
- Sponsor
- Chulabhorn Royal Academy
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of favipiravir in coronavirus disease 2019 (COVID-19), sponsored by Chulabhorn Royal Academy. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20210909002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210909002.